RCUS Stock: Price, Earnings History and SEC Filings
Arcus Biosciences, Inc. (RCUS) last traded at $18.19, down 2.26% on the latest session and down 29.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.72 against an analyst estimate of $-0.98, a beat of 26.5%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
RCUS earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $-0.72 | $-0.98 | +26.53% |
| Mar 2026 | May 5, 2026 | $-1.02 | $-0.92 | -10.87% |
| Dec 2025 | Feb 25, 2026 | $-0.89 | $-1.11 | +19.82% |
| Sep 2025 | Oct 28, 2025 | $-1.27 | $-1.33 | +4.51% |
RCUS beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
How RCUS reacts to earnings
Across its last 8 earnings releases, RCUS moved 1.8% on average the next session, in either direction. It rose after 3 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-10-21 | After close | +1.36% |
| 2026-08-05 | After close | +2.27% |
| 2026-05-05 | After close | -0.23% |
| 2026-02-25 | After close | -3.60% |
| 2025-10-28 | After close | +2.06% |
| 2025-08-06 | After close | -2.21% |
| 2025-05-06 | After close | -1.35% |
| 2025-02-25 | After close | -0.98% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
RCUS financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $33M | -$353M | -$484M | -1069.7% | $-3.29 |
| 2024 | $51M | -$283M | -$176M | -554.9% | $-3.14 |
| 2023 | $37M | -$307M | -$330M | -829.7% | $-4.15 |
| 2022 | $38M | -$267M | $432M | -702.6% | $-3.71 |
| 2021 | $383M | $53M | -$282M | 13.8% | $0.71 |
| 2020 | $78M | -$123M | $108M | -157.7% | $-2.24 |
| 2019 | $15M | -$85M | -$75M | -564.7% | $-1.93 |
| 2018 | $8M | -$50M | -$47M | -593.7% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for RCUS
- 8-K · Oct 23, 2026Other events, Financial statements and exhibits
- 424B5 · Oct 22, 2026
- 424B5 · Oct 21, 2026
- 8-K · Oct 21, 2026Results of operations
- 8-K · Oct 20, 2026Other events
- 10-Q · Aug 5, 2026
- 8-K · Aug 5, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 12, 2026Shareholder vote
- 10-Q · May 5, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
Insider filing activity
RCUS insiders filed 1 Form 4 report in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
RCUS news
- Arcus Biosciences Announces New Employment Inducement GrantsOct 26, 2026 · finance.yahoo.com
- How Investors May Respond To Arcus Biosciences (RCUS) $250 Million Share SaleOct 24, 2026 · finance.yahoo.com
- Arcus Biosciences (RCUS) Stock Looks Stretched As Casdatifan Trial Data ImpressesOct 24, 2026 · finance.yahoo.com
- Arcus Biosciences Completes $269 Million Common Stock OfferingOct 24, 2026 · theglobeandmail.com
- Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common StockOct 22, 2026 · finance.yahoo.com
- Arcus Biosciences stock falls on public offering announcementOct 21, 2026 · finance.yahoo.com
- Arcus Biosciences Announces Commencement of Public Offering of Common StockOct 21, 2026 · finance.yahoo.com
- William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates CoverageOct 21, 2026 · finance.yahoo.com
About Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (RCUS) is a US-listed public company on NYSE. The SEC classifies its business as Pharmaceutical Preparations. It is incorporated in DE. Its fiscal year ends in December.